First, despite the widespread use of IFN-α in the treatment of chronic hepatitis B, its specific immunomodulatory mechanisms, especially regarding different responses between individuals, have not been fully elucidated. The gene discussed is IFNA17; the disease is chronic hepatitis B virus infection.